vascuCAP vs Tempus ECG-AF
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A (vascuCAP) specializes in analyzing CT angiograms to quantify plaque composition and assess general cardiovascular risk, supporting treatment decisions for existing conditions. In contrast, Tool B (Tempus ECG-AF) focuses on analyzing 12-lead ECGs to identify older patients at risk of developing new-onset atrial fibrillation. While both are cardiology AI tools, they address different cardiovascular conditions and utilize distinct diagnostic modalities.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
vascuCAP (now ElucidVivo/PlaqueIQ) is designed for non-invasive CT angiography analysis to quantify plaque composition and assess cardiovascular risk, aiming to optimize treatment decisions for stroke and heart attack prevention. Tempus ECG-AF analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing new onset atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up.
vascuCAP analyzes non-invasive CT angiography images to characterize plaque tissues and arterial vessels. Tempus ECG-AF processes standard 12-lead ECG recordings collected at a healthcare facility.
vascuCAP is intended for patients with known or suspected cardiovascular disease, for whom CT angiograms are available for plaque assessment and risk stratification. Tempus ECG-AF is specifically for patients aged 65 or older who do not have a known history of AF, pacemakers, ICDs, or recent cardiac surgery.
vascuCAP provides histologically-validated quantification of plaque components, such as lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage, along with 3D visualization for risk stratification of stroke and heart attack. Tempus ECG-AF offers an AI-based risk assessment, reporting whether a patient is at 'increased risk' or 'no increased risk' of experiencing new onset AF within 12 months, which should be interpreted with other clinical information.
Yes, Elucid's PlaqueIQ (formerly vascuCAP) has new Category I CPT code 75577 for coronary plaque analysis from CCTA, effective January 1, 2026, with national average payments of $1,021 for imaging centers/physician offices and $951 for hospital outpatient settings. Yes, CMS reimbursement is available for Tempus ECG-AF, with CPT codes 0764T and 0765T assigned to APC 5734, and a Medicare rate of $128.90, effective January 1, 2025.
vascuCAP features AI-enabled CT angiogram analysis with histologically-validated plaque quantification and characterization, using a biobank of tissue specimens as an objective truth standard. Tempus ECG-AF employs an AI-based algorithm trained on an extensive dataset of over 1.5 million ECGs from more than 500,000 patients to detect signs associated with new onset AF.